Veloxis Pharmaceuticals has agreed to pay over $46 million to settle allegations of involvement in kickback schemes. The Office of Public Affairs announced that this resolution addresses both criminal and civil liabilities related to improper financial incentives provided to healthcare providers and institutions. These kickbacks were aimed at promoting the company’s pharmaceutical products, potentially compromising the integrity of medical decision-making and jeopardizing patient welfare. The settlement underscores Veloxis’s commitment to compliance and ethical practices in the pharmaceutical industry. It also highlights the ongoing efforts of regulatory authorities to combat corruption in healthcare. Through this resolution, Veloxis seeks to rectify past conduct and reinforce its dedication to responsible business practices moving forward.
For more details and the full reference, visit the source link below: